Keros Therapeutics(KROS)
$11.39-0.61 (-5.08%)
KROS
Keros Therapeutics financials statements
$11.39
At close:-0.61 (-5.08%)
Want to see KROS full AI Analyst Report?
Keros Therapeutics (KROS) Ratios
371 Followers
Keros Therapeutics Ratios
KROS's free cash flow for Q3 2026 was $3.33M. For the 2026 fiscal year, KROS's free cash flow was decreased by $-59.00K and operating cash flow was $3.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 |
| Quick Ratio | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 |
| Cash Ratio | 14.08 | 20.40 | 13.59 | 16.86 | 19.42 |
| Solvency Ratio | 2.54 | -4.20 | -4.02 | -3.54 | -4.83 |
| Operating Cash Flow Ratio | 5.27 | -5.86 | -5.11 | -4.23 | -5.25 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 280.55M | $ 544.56M | $ 309.48M | $ 256.41M | $ 239.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.03 | 0.04 | 0.04 | 0.00 |
| Debt-to-Equity Ratio | 0.06 | 0.03 | 0.04 | 0.05 | 0.00 |
| Debt-to-Capital Ratio | 0.05 | 0.03 | 0.04 | 0.05 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.08 | 1.11 | 1.11 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -104004.00 | -14590.50 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -114790.00 | -14093.25 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.45 | 0.50 | 0.49 | 0.53 | 0.05 |
| Net Debt to EBITDA | -2.90 | 2.91 | 2.08 | 2.56 | 4.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.38% | 100.00% | 100.00% | 0.00% | 100.00% |
| EBIT Margin | 37.65% | -5269.10% | -101319.21% | 0.00% | -282.23% |
| EBITDA Margin | 38.27% | -5234.48% | -100779.47% | 0.00% | -280.35% |
| Operating Profit Margin | 28.94% | -5938.96% | -112543.71% | 0.00% | -280.46% |
| Pretax Profit Margin | 37.65% | -5269.10% | -101319.21% | 0.00% | -282.25% |
| Net Profit Margin | 35.65% | -5277.55% | -101319.21% | 0.00% | -292.26% |
| Continuous Operations Profit Margin | 35.65% | -5277.55% | -101319.21% | 0.00% | -292.26% |
| Net Income Per EBT | 94.69% | 100.16% | 100.00% | 100.00% | 103.54% |
| EBT Per EBIT | 130.12% | 88.72% | 90.03% | 91.19% | 100.64% |
| Return on Assets (ROA) | 25.74% | -30.42% | -41.35% | -34.12% | -23.01% |
| Return on Equity (ROE) | 28.70% | -32.78% | -46.05% | -37.73% | -24.16% |
| Return on Capital Employed (ROCE) | 22.24% | -35.83% | -49.17% | -39.55% | -23.16% |
| Return on Invested Capital (ROIC) | 20.90% | -35.71% | -49.02% | -39.49% | -23.08% |
| Return on Tangible Assets | 25.74% | -30.42% | -41.35% | -34.12% | -23.01% |
| Earnings Yield | 11.48% | -31.61% | -13.07% | -8.64% | -4.30% |
| Efficiency Ratios | |||||
| Receivables Turnover | 38.30 | 0.80 | 0.14 | 0.00 | 1.10 |
| Payables Turnover | 0.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 11.55 | 0.15 | 0.01 | 0.00 | 8.37 |
| Asset Turnover | 0.72 | 0.01 | 0.00 | 0.00 | 0.08 |
| Working Capital Turnover Ratio | 0.57 | 0.01 | 0.00 | 0.00 | 0.08 |
| Cash Conversion Cycle | -466.25 | 458.15 | 2637.19 | 0.00 | 330.44 |
| Days of Sales Outstanding | 9.53 | 458.15 | 2637.19 | 0.00 | 330.44 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 475.78 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 9.53 | 458.15 | 2637.19 | 0.00 | 330.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.89 | -4.30 | -4.23 | -2.78 | -2.66 |
| Free Cash Flow Per Share | 2.85 | -4.35 | -4.31 | -2.82 | -2.71 |
| Dividend Paid and CapEx Coverage Ratio | 69.31 | -83.31 | -50.53 | -56.46 | -60.69 |
| Capital Expenditure Coverage Ratio | 69.31 | -83.31 | -50.53 | -56.46 | -60.69 |
| Operating Cash Flow Coverage Ratio | 6.37 | -8.53 | -8.62 | -5.28 | -56.86 |
| Operating Cash Flow to Sales Ratio | 0.44 | -45.32 | -824.56 | 0.00 | -3.09 |
| Free Cash Flow Yield | 13.98% | -27.47% | -10.84% | -5.88% | -4.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 8.70 | -3.17 | -7.65 | -11.58 | -23.24 |
| Price-to-Sales (P/S) Ratio | 3.11 | 166.94 | 7753.76 | 0.00 | 67.92 |
| Price-to-Book (P/B) Ratio | 2.50 | 1.04 | 3.52 | 4.37 | 5.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.15 | -3.64 | -9.22 | -17.00 | -21.61 |
| Price-to-Operating Cash Flow Ratio | 7.05 | -3.68 | -9.40 | -17.30 | -21.97 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.82 | -0.30 | -0.18 | 1.66 |
| Enterprise Value Multiple | 5.22 | -0.28 | -5.61 | -9.10 | -20.17 |
| Enterprise Value | 487.29M | 51.57M | 854.11M | 946.29M | 1.14B |
| EV to EBITDA | 5.22 | -0.28 | -5.61 | -9.10 | -20.17 |
| EV to Sales | 2.00 | 14.53 | 5656.39 | 0.00 | 56.53 |
| EV to Free Cash Flow | 4.60 | -0.32 | -6.73 | -13.27 | -17.99 |
| EV to Operating Cash Flow | 4.53 | -0.32 | -6.86 | -13.51 | -18.28 |
| Tangible Book Value Per Share | 8.14 | 15.27 | 11.28 | 10.99 | 10.42 |
| Shareholders’ Equity Per Share | 8.14 | 15.27 | 11.28 | 10.99 | 10.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.05 | -0.00 | 0.00 | 0.00 | -0.04 |
| Revenue Per Share | 6.56 | 0.09 | 0.01 | 0.00 | 0.86 |
| Net Income Per Share | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 |
| Tax Burden | 0.95 | 1.00 | 1.00 | 1.00 | 1.04 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.53 | 48.91 | 895.75 | 0.00 | 2.74 |
| SG&A to Revenue | 0.19 | 11.48 | 230.69 | 0.00 | 1.06 |
| Stock-Based Compensation to Revenue | 0.12 | 9.82 | 190.48 | 0.00 | 0.58 |
| Income Quality | 1.24 | 0.86 | 0.81 | 0.67 | 1.06 |
Currency in USD

